Skip to content

BRIACELL THERAPEUTICS CORP.: 10-Q filed 2024-12-16

What BRIACELL THERAPEUTICS CORP. reported in its quarterly report filed 2024-12-16 (fiscal Q1 2025): 31 published measures, 62 facts as tagged in accession 0001493152-24-050214.

This filing

Form
10-Q (quarterly report)
Filed
2024-12-16
Fiscal period
fiscal Q1 2025
Accession
0001493152-24-050214 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All BRIACELL THERAPEUTICS CORP. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2024-10-3110,414,330USD
At 2024-07-315,872,261USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2024-10-315,792,265USD
At 2024-07-31862,089USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2024-08-01 to 2024-10-31-5,802,175USD92
2023-08-01 to 2023-10-316,001,543USD92

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2024-08-01 to 2024-10-31-6,955,076USD92
2023-08-01 to 2023-10-31-7,605,245USD92

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2024-08-01 to 2024-10-3111,960,252USD92

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2024-08-01 to 2024-10-31-75,000USD92

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2024-10-31-91,245,872USD
At 2024-07-31-85,443,697USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2024-08-01 to 2024-10-3126,641,036shares92
2023-08-01 to 2023-10-3115,981,726shares92

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2024-08-01 to 2024-10-3126,641,036shares92
2023-08-01 to 2023-10-3116,674,891shares92

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2024-08-01 to 2024-10-31-0.22USD/shares92
2023-08-01 to 2023-10-310.38USD/shares92

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2024-08-01 to 2024-10-31-0.22USD/shares92
2023-08-01 to 2023-10-31-0.5USD/shares92

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2024-10-31365,336USD
At 2024-07-31388,175USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2024-08-01 to 2024-10-31266,971USD92
2023-08-01 to 2023-10-31533,816USD92

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2024-08-01 to 2024-10-31-5,152,832USD92
2023-08-01 to 2023-10-31-8,503,028USD92

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2024-10-318,219,095USD
At 2024-07-313,653,854USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2024-10-314,988,636USD
At 2024-07-317,461,157USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2024-08-01 to 2024-10-315,152,832USD92
2023-08-01 to 2023-10-318,503,028USD92

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2024-08-01 to 2024-10-313,665,341USD92
2023-08-01 to 2023-10-316,857,257USD92

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2024-10-3136,183,161shares
At 2024-07-3118,284,661shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

PeriodValueUnitDays
At 2024-10-315,792,265USD
At 2024-07-31862,089USD
At 2023-10-3113,645,847USD
At 2023-07-3121,251,092USD

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

PeriodValueUnitDays
At 2024-10-31-138,684USD
At 2024-07-31-138,684USD

Total equity including noncontrolling interests

Equity including the portion attributable to noncontrolling interests. It is larger than or equal to parent stockholders equity and is not market capitalization.

PeriodValueUnitDays
At 2024-10-313,713,015USD
At 2024-07-31-2,684,932USD
At 2023-10-312,516,300USD
At 2023-07-31-3,777,181USD

Net intangible assets excluding goodwill

Intangible assets other than goodwill after amortization and impairment. Internally developed intangibles are usually not recognized, so this understates what a company relies on.

PeriodValueUnitDays
At 2024-10-31195,978USD
At 2024-07-31199,796USD

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

PeriodValueUnitDays
2024-08-01 to 2024-10-31-5,829,276USD92
2023-08-01 to 2023-10-315,958,872USD92

Net income available to common stockholders

Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.

PeriodValueUnitDays
2024-08-01 to 2024-10-31-5,802,175USD92
2023-08-01 to 2023-10-316,001,543USD92

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2024-08-01 to 2024-10-311,487,491USD92
2023-08-01 to 2023-10-311,645,771USD92

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2024-08-01 to 2024-10-3122,839USD92

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2024-08-01 to 2024-10-3111,714USD92
2023-08-01 to 2023-10-31179,822USD92

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2024-08-01 to 2024-10-3111,667,001USD92

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

PeriodValueUnitDays
2024-08-01 to 2024-10-31-736,788USD92
2023-08-01 to 2023-10-312,537USD92

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2024-08-01 to 2024-10-31-2,936,813USD92
2023-08-01 to 2023-10-31-689,824USD92

Inspect the source

Entity
BRIACELL THERAPEUTICS CORP. / CIK 0001610820
Captured
2026-09-20T09:26:46.138Z
SEC response SHA-256
9b120e952e46202c087d84b15420884d11dabee9617ee209952acee5219f65e1

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001610820.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))